ZA868251B - Dna sequences,recombinant dna molecules and processes for producing mullerian inhibiting substance-like polypeptides - Google Patents

Dna sequences,recombinant dna molecules and processes for producing mullerian inhibiting substance-like polypeptides

Info

Publication number
ZA868251B
ZA868251B ZA868251A ZA868251A ZA868251B ZA 868251 B ZA868251 B ZA 868251B ZA 868251 A ZA868251 A ZA 868251A ZA 868251 A ZA868251 A ZA 868251A ZA 868251 B ZA868251 B ZA 868251B
Authority
ZA
South Africa
Prior art keywords
polypeptides
processes
inhibiting substance
dna sequences
sequences
Prior art date
Application number
ZA868251A
Other languages
English (en)
Inventor
Richard L Cate
Patricia K Donahoe
Original Assignee
Biogen Nv
Gen Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Nv, Gen Hospital Corp filed Critical Biogen Nv
Publication of ZA868251B publication Critical patent/ZA868251B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
ZA868251A 1985-10-30 1986-10-29 Dna sequences,recombinant dna molecules and processes for producing mullerian inhibiting substance-like polypeptides ZA868251B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/792,880 US5047336A (en) 1985-10-30 1985-10-30 DNA sequences, recombinant DNA molecules and processes for producing mullerian inhibiting substance-like polypeptides

Publications (1)

Publication Number Publication Date
ZA868251B true ZA868251B (en) 1988-09-28

Family

ID=25158349

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA868251A ZA868251B (en) 1985-10-30 1986-10-29 Dna sequences,recombinant dna molecules and processes for producing mullerian inhibiting substance-like polypeptides

Country Status (13)

Country Link
US (1) US5047336A (pt)
EP (1) EP0221761B1 (pt)
JP (2) JPH0720431B2 (pt)
KR (1) KR870004143A (pt)
AT (1) ATE119915T1 (pt)
AU (1) AU606584B2 (pt)
CA (1) CA1307753C (pt)
DE (1) DE3650266T2 (pt)
DK (1) DK517986A (pt)
HU (1) HUT43627A (pt)
IL (1) IL80451A0 (pt)
PT (1) PT83655B (pt)
ZA (1) ZA868251B (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5047336A (en) * 1985-10-30 1991-09-10 Biogen, Inc. DNA sequences, recombinant DNA molecules and processes for producing mullerian inhibiting substance-like polypeptides
AU622891B2 (en) * 1985-10-30 1992-04-30 Biogen, Inc. Cleaved dimers of mullerian inhibiting substance-like polypeptides
US5427780A (en) * 1985-10-30 1995-06-27 Biogen, Inc. Composition comprising Mullerian inhibiting substance-like polypeptides
US5185441A (en) * 1988-08-26 1993-02-09 Biogen, Inc. Dna sequences, recombinant dna molecules and processes for producing pi-linked lymphocyte function associated antigen-3
US5661126A (en) * 1989-01-19 1997-08-26 The General Hospital Corporation Use of mullerian inhibiting substance for treating certain tumors and for modulating class I major histocompatibility antigen expression
US5349058A (en) * 1990-02-06 1994-09-20 E. R. Squibb & Sons, Inc. Nucleic acid encoding human mevalonate kinase
US5281520A (en) * 1990-09-12 1994-01-25 Zymogenetics, Inc. Method for producing acyloxyacyl hydrolase
US5310880A (en) * 1991-04-12 1994-05-10 The General Hospital Corporation Purification of Mullerian inhibiting substance
US6764681B2 (en) * 1991-10-07 2004-07-20 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
WO1993019177A1 (en) * 1992-03-18 1993-09-30 The General Hospital Corporation FOUR NOVEL RECEPTORS OF THE TGF-β RECEPTOR FAMILY
CN100473417C (zh) * 1998-08-31 2009-04-01 安斯泰来美国有限责任公司 Cd2-结合剂调节记忆效应t-细胞的制药用途和组合物
US20020119921A1 (en) * 1999-03-31 2002-08-29 Michael Streit Thrombospondin-2 and uses thereof
US6692738B2 (en) 2000-01-27 2004-02-17 The General Hospital Corporation Delivery of therapeutic biologicals from implantable tissue matrices
CA2384991A1 (en) * 1999-09-14 2001-03-22 The General Hospital Corporation Use of mullerian inhibiting substance for treating excess androgen states
WO2002099067A2 (en) * 2001-06-05 2002-12-12 Oishi Karen K Gene expression and production of tgf-b proteins including bioactive mullerian inhibiting substance from plants
CA2454618C (en) * 2001-07-24 2012-04-03 Biogen Idec Ma, Inc. Methods for treating or preventing sclerotic disorders using cd2-binding agents
US20040151693A1 (en) * 2002-08-23 2004-08-05 The General Hospital Corporation Use of mullerian inhibiting substance and interferon for treating tumors
BRPI0507404A (pt) * 2004-02-06 2007-06-26 Astellas Us Llc método de tratamento de um indivìduo que tem psorìase e kit
EP1747291A2 (en) * 2004-05-04 2007-01-31 Genaissance Pharmaceuticals, Inc. Haplotype markers and methods of using the same to determine response to treatment
US7662921B2 (en) * 2004-05-07 2010-02-16 Astellas Us Llc Methods of treating viral disorders
US20060162026A1 (en) * 2004-12-23 2006-07-20 Karen Oishi Expressing TGF-beta proteins in plant plastids
AU2005211556A1 (en) * 2005-03-24 2006-10-12 Otago Innovation Limited Method Of Modulation
JP2009515832A (ja) * 2005-10-26 2009-04-16 オタゴ イノベーション リミテッド 神経変性疾患の治療のためのミュラー管抑制物質（ｍｉｓ）受容体のモジュレーション方法
WO2008116161A2 (en) 2007-03-22 2008-09-25 The General Hospital Corporation Pyrazoloanthrone and derivatives thereof for the treatment of cancer expressing 'mullerian inhibiting substance' type ii receptor (misrii) and of excess androgen states
WO2009012357A2 (en) 2007-07-17 2009-01-22 The General Hospital Corporation Methods to identify and enrich for populations of ovarian cancer stem cells and somatic ovarian stem cells and uses thereof
ITRM20120285A1 (it) 2012-06-18 2013-12-19 Alfonso Baldi Ormone anti-mulleriano.
ES2853935T3 (es) * 2013-03-12 2021-09-20 Massachusetts Gen Hospital Proteínas modificadas de sustancia inhibidora muleriana (MIS) y usos de las mismas para el tratamiento de enfermedades
RU2616273C1 (ru) * 2016-04-21 2017-04-13 Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства Синтетическая ДНК, кодирующая антимюллеров гормон человека, содержащий ее экспрессионный вектор pTVK4pu/MISOPT и штамм клеток яичников китайского хомячка CHO-MIS - продуцент рекомбинантного антимюллерового гормона человека

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4510131A (en) * 1981-07-29 1985-04-09 The General Hospital Corporation Purified Mullerian Inhibiting Substance and method of use
US4404188A (en) * 1981-07-29 1983-09-13 Massachusetts General Hospital Purified Mullerian Inhibiting Substance and method of purification
US4442205A (en) * 1981-09-22 1984-04-10 The United States Of America As Represented By The Department Of Health And Human Services Simian virus recombinant that directs the synthesis of hepatitis B surface antigen
US4487833A (en) * 1982-03-01 1984-12-11 The General Hospital Corporation Method of preparing hybridomas and of purifying immunogenic materials
US4740587A (en) * 1985-07-18 1988-04-26 The Salk Institute For Biological Studies Inhibin and method of purifying same
US5047336A (en) * 1985-10-30 1991-09-10 Biogen, Inc. DNA sequences, recombinant DNA molecules and processes for producing mullerian inhibiting substance-like polypeptides

Also Published As

Publication number Publication date
HUT43627A (en) 1987-11-30
PT83655B (en) 1988-11-29
ATE119915T1 (de) 1995-04-15
JP2541761B2 (ja) 1996-10-09
JPS62190084A (ja) 1987-08-20
KR870004143A (ko) 1987-05-07
DE3650266D1 (de) 1995-04-20
CA1307753C (en) 1992-09-22
DE3650266T2 (de) 1995-08-31
AU606584B2 (en) 1991-02-14
PT83655A (en) 1986-11-01
EP0221761A3 (en) 1988-10-12
US5047336A (en) 1991-09-10
EP0221761A2 (en) 1987-05-13
IL80451A0 (en) 1987-01-30
JPH0720431B2 (ja) 1995-03-08
JPH06133793A (ja) 1994-05-17
DK517986D0 (da) 1986-10-29
EP0221761B1 (en) 1995-03-15
AU6452186A (en) 1987-05-07
DK517986A (da) 1987-05-01

Similar Documents

Publication Publication Date Title
EP0221761A3 (en) Dna sequences, recombinant dna molecules and processes for producing mullerian inhibiting substance-like polypeptides
ZA822855B (en) Bacillus cloning vectors,recombinant dna molecules,bacillus hosts transformed with them and methods for expressing foreign dna sequences and producing polypeptides coded thereby
CY1346A (en) Dna sequences,recombinant dna molecules and processes for producing human interferon-like polypeptides
ZA831094B (en) Dna sequences,recombinant dna molecules and processes for producing human immune interferon-like polypeptides
TW581808B (en) Compounds for immunotherapy of prostate cancer and methods for their use
ES8802159A1 (es) Un procedimiento de producir un acido desoxirribonucleico (adn)que tiene o contiene una secuencia de base que codificaun polipeptido de factor de necrosis tumoral de humano
HK1013847A1 (en) Gdf-1 and uog-1 proteins
BG100771A (en) Hematopoeic protein and ways and methods for its preparation
ZA86217B (en) Dna sequences,recombinant dna molecules and processes for producing human lipocortin-like polypeptides
PL254399A1 (en) Method of isolating a neoplasm necrosis effecting factor
AU4778101A (en) Novel polypeptides, and nucleic acids encoding the same
IL70414A (en) Polypeptide having human h2-relaxin activity,double-stranded dna fragments coding therefor,vectors containing the dna fragments and methods for preparing the polypeptide,dna fragments and vectors
NZ510356A (en) Molecules designated LDCAM
EP0091527A3 (en) Dna sequences, recombinant dna molecules and processes for producing human serum albumin-like polypeptides
ES8708013A1 (es) Procedimiento para preparar plasmidos de expresion prhw11 y prhw12
ES8704207A1 (es) Procedimiento para preparar una molecula de adn
EP0170266A3 (en) Process for producing protein, and vector, recombinant dna and transformant used therefor
EP0324788A4 (en) LAMININE BINDING PEPTIDE FRAGMENTS.
EP0960128A4 (en) Gene product overexpressed in cancer cells
IL65623A0 (en) Bacillus cloning vectors,recombinant dna molecules,bacillus hosts transformed with them and methods for expressing foreign dna sequences and producing poly-peptides coded thereby
ATE75255T1 (de) Peptid und dafuer kodierendes gen.
ZA812189B (en) Dna sequences, recombinant dna molecules and processes for producing human fibroblast interferon-like polypeptides
KE3669A (en) Dna sequences,recombinant dna molecules and processes for producing human interferon-alpha like polypeptides
NO871737D0 (no) Rekombinant virus, polypeptid samt dna molekyl med kodingssekvens for dette polypeptid.